Topical Sirolimus to Treat Tuberous Sclerosis Complex (TSC)

被引：12
作者：
Darling, Thomas N. [1 ]
机构：
[1] Uniformed Serv Univ Hlth Sci, Dept Dermatol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA
来源：
JAMA DERMATOLOGY | 2018年 / 154卷 / 07期
关键词：
LONG-TERM TREATMENT; RAPAMYCIN; SKIN; INHIBITORS; EFFICACY;
D O I：
10.1001/jamadermatol.2018.0465
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：761 / 762
页数：2
相关论文
共 15 条
  • [1] Macrolactam immunomodulators for topical treatment of inflammatory skin diseases
    Bornhövd, E
    Burgdorf, WHC
    Wollenberg, A
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2001, 45 (05) : 736 - 743
  • [2] Inhibition of Akt Enhances the Chemopreventive Effects of Topical Rapamycin in Mouse Skin
    Dickinson, Sally E.
    Janda, Jaroslav
    Criswell, Jane
    Blohm-Mangone, Karen
    Olson, Erik R.
    Liu, Zhonglin
    Barber, Christy
    Petricoin, Emanuel F., III
    Calvert, Valerie S.
    Einspahr, Janine
    Dickinson, Jesse E.
    Stratton, Steven P.
    Curiel-Lewandrowski, Clara
    Saboda, Kathylynn
    Hu, Chengcheng
    Bode, Ann M.
    Dong, Zigang
    Alberts, David S.
    Bowden, G. Timothy
    [J]. CANCER PREVENTION RESEARCH, 2016, 9 (03) : 215 - 224
  • [3] mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders
    Franz, David N.
    Capal, Jamie K.
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2017, 12
  • [4] Haemel AK, 2010, ARCH DERMATOL, V146, P715, DOI 10.1001/archdermatol.2010.125
  • [5] Efficacy of Topical Sirolimus (Rapamycin) for the Treatment of Microcystic Lymphatic Malformations
    Ivars, Marta
    Redondo, Pedro
    [J]. JAMA DERMATOLOGY, 2017, 153 (01) : 103 - 105
  • [6] Topical Use of Mammalian Target of Rapamycin (mTOR) Inhibitors in Tuberous Sclerosis Complex-A Comprehensive Review of the Literature
    Jozwiak, Sergiusz
    Sadowski, Krzysztof
    Kotulska, Katarzyna
    Schwartz, Robert A.
    [J]. PEDIATRIC NEUROLOGY, 2016, 61 : 21 - 27
  • [7] Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex The TREATMENT Randomized Clinical Trial
    Koenig, Mary Kay
    Bell, Cynthia S.
    Hebert, Adelaide A.
    Roberson, Joan
    Samuels, Joshua A.
    Slopis, John M.
    Tate, Patti
    Northrup, Hope
    [J]. JAMA DERMATOLOGY, 2018, 154 (07) : 773 - 780
  • [8] Long-term treatment of cutaneous manifestations of tuberous sclerosis complex with topical 1% sirolimus cream: A prospective study of 25 patients
    Malissen, Nausicaa
    Vergely, Laurence
    Simon, Marguerite
    Roubertie, Agathe
    Malinge, Marie-Claire
    Bessis, Didier
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 77 (03) : 464 - +
  • [9] Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus
    Nathan, Neera
    Wang, Ji-an
    Li, Shaowei
    Cowen, Edward W.
    Haughey, Mary
    Moss, Joel
    Darling, Thomas N.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 73 (05) : 802 - 808
  • [10] Applying the Lessons of Tuberous Sclerosis: The 2015 Hower Award Lecture
    Roach, E. Steve
    [J]. PEDIATRIC NEUROLOGY, 2016, 63 : 6 - 22
12